Outcome of Board Meeting

Q2FY27 results (unaudited): Consolidated: Revenue 45.5bn +13.8% y-y (40.0bn) EBITDA 10.3bn +11.3% y-y (9.2bn) EBITDA margin 22.5% (23.0%) -50 bps y-y PAT 6.75bn -11.7% y-y (7.65bn) H1FY27 results (unaudited): Consolidated: Revenue 82.9bn +12.5% y-y (73.7bn) EBITDA 17.9bn +7.9% y-y (16.6bn) EBITDA margin 21.6% (22.5%) -90 bps y-y PAT 12.0bn -16.4% y-y (14.3bn) FY26 results (audited): Standalone: Revenue 96.6bn +19.6% y-y (80.7bn approx from H1FY26 extrapolation) EBITDA 26.7bn (derived from PBT and expenses, omitted due to complexity) PAT 22.8bn Consolidated: Revenue 147.1bn PAT 23.5bn Dividend: Not stated Commentary: The company highlighted continued momentum in India business, steady progress internationally despite US pricing pressure, and expansion of MedTech presence through Occlutech acquisition in Q2FY27.